Alternative methods and strategies to reduce, refine, and replace animal use for veterinary vaccine post-licensing safety testing: state of the science and future directions

Jodie Kulpa-Eddy , Geetha Srinivas , Marlies Halder , Karen Brown , Hans Draayer , Jeffrey Galvin , Ivo Claassen , Glen Gifford , Ralph Woodland , Vivian Doelling , Brett Jones , William S Stokes
{"title":"Alternative methods and strategies to reduce, refine, and replace animal use for veterinary vaccine post-licensing safety testing: state of the science and future directions","authors":"Jodie Kulpa-Eddy ,&nbsp;Geetha Srinivas ,&nbsp;Marlies Halder ,&nbsp;Karen Brown ,&nbsp;Hans Draayer ,&nbsp;Jeffrey Galvin ,&nbsp;Ivo Claassen ,&nbsp;Glen Gifford ,&nbsp;Ralph Woodland ,&nbsp;Vivian Doelling ,&nbsp;Brett Jones ,&nbsp;William S Stokes","doi":"10.1016/j.provac.2011.10.007","DOIUrl":null,"url":null,"abstract":"<div><p>NICEATM and ICCVAM convened an international workshop to review the state of the science of human and veterinary vaccine potency and safety testing methods and to identify opportunities to advance new and improved methods that can further reduce, refine, and replace animal use. Six topics were addressed in detail by speakers and workshop participants and are reported in a series of six reports. This workshop report, the last in the series, addresses methods and strategies for veterinary vaccine post-licensing safety testing that can reduce, refine, and replace animal use (the 3Rs). It also provides recommendations for priority research and other activities necessary to advance the development and/or implementation of 3Rs methods for veterinary vaccine post-licensing safety testing. Workshop participants gave priority for future efforts to vaccines that (1) use large numbers of animals per test, (2) produce large numbers of serials annually, (3) use additional animals for safety testing. They also prioritized poultry vaccines for which <em>in vivo</em> extraneous agent testing is still performed, adjuvanted vaccines that cause a site reaction, and vaccines that are well characterized. Vaccines identified as the highest priorities were those for avian diseases, rabies, <em>Clostridium spp</em>., and subunit protein and DNA vaccines, in addition to modified live viral products that do not contain excipients. Workshop participants recommended priority research, development, and validation activities to address critical knowledge and data gaps, including opportunities to apply new science and technology. Recommendations included further assessment of the need for a general safety test; expanded application of primary cell culture and polymerase chain reaction (PCR) techniques to replace <em>in vivo</em> chicken tests for extraneous agents; development of in-process safety testing to verify detoxification of selected vaccines; and further investigation of cell-based assays to measure residual toxicity. Implementation of the workshop recommendations is expected to advance alternative methods for veterinary vaccine post-licensing safety testing that will benefit animal welfare and reduce or replace animal use while ensuring continued protection of human and animal health.</p></div>","PeriodicalId":89221,"journal":{"name":"Procedia in vaccinology","volume":"5 ","pages":"Pages 106-119"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.provac.2011.10.007","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Procedia in vaccinology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1877282X11000257","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 10

Abstract

NICEATM and ICCVAM convened an international workshop to review the state of the science of human and veterinary vaccine potency and safety testing methods and to identify opportunities to advance new and improved methods that can further reduce, refine, and replace animal use. Six topics were addressed in detail by speakers and workshop participants and are reported in a series of six reports. This workshop report, the last in the series, addresses methods and strategies for veterinary vaccine post-licensing safety testing that can reduce, refine, and replace animal use (the 3Rs). It also provides recommendations for priority research and other activities necessary to advance the development and/or implementation of 3Rs methods for veterinary vaccine post-licensing safety testing. Workshop participants gave priority for future efforts to vaccines that (1) use large numbers of animals per test, (2) produce large numbers of serials annually, (3) use additional animals for safety testing. They also prioritized poultry vaccines for which in vivo extraneous agent testing is still performed, adjuvanted vaccines that cause a site reaction, and vaccines that are well characterized. Vaccines identified as the highest priorities were those for avian diseases, rabies, Clostridium spp., and subunit protein and DNA vaccines, in addition to modified live viral products that do not contain excipients. Workshop participants recommended priority research, development, and validation activities to address critical knowledge and data gaps, including opportunities to apply new science and technology. Recommendations included further assessment of the need for a general safety test; expanded application of primary cell culture and polymerase chain reaction (PCR) techniques to replace in vivo chicken tests for extraneous agents; development of in-process safety testing to verify detoxification of selected vaccines; and further investigation of cell-based assays to measure residual toxicity. Implementation of the workshop recommendations is expected to advance alternative methods for veterinary vaccine post-licensing safety testing that will benefit animal welfare and reduce or replace animal use while ensuring continued protection of human and animal health.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
减少、改进和替代兽医疫苗许可后安全测试动物使用的替代方法和战略:科学现状和未来方向
NICEATM和iccvm召开了一次国际讲习班,审查人用和兽用疫苗效力和安全性测试方法的科学现状,并确定推进可进一步减少、改进和取代动物使用的新改进方法的机会。发言者和讲习班参与者详细讨论了六个专题,并在一系列六份报告中予以报告。本研讨会报告是本系列的最后一篇,讨论了可以减少、改进和取代动物使用的兽医疫苗许可后安全测试的方法和策略(3r)。它还为优先研究和其他必要活动提供建议,以推进兽医疫苗许可后安全检测3Rs方法的开发和/或实施。讲习班与会者优先考虑了以下方面的未来工作:(1)每次试验使用大量动物,(2)每年生产大量系列疫苗,(3)使用额外动物进行安全试验。他们还优先考虑仍在进行体内外源物测试的家禽疫苗、引起局部反应的佐剂疫苗和具有良好特征的疫苗。除不含赋形剂的改性活病毒产品外,被确定为最优先事项的疫苗包括禽病疫苗、狂犬病疫苗、梭状芽胞杆菌疫苗、亚基蛋白疫苗和DNA疫苗。研讨会参与者建议优先研究、开发和验证活动,以解决关键的知识和数据差距,包括应用新科学和技术的机会。建议包括进一步评估进行一般安全测试的必要性;扩大原代细胞培养和聚合酶链反应(PCR)技术的应用,以取代鸡体内对外来病原体的检测;开展过程中安全检测,以核实选定疫苗的解毒作用;并进一步研究以细胞为基础的检测残余毒性的方法。实施讲习班建议预计将推动兽医疫苗许可后安全测试的替代方法,这将有利于动物福利,减少或取代动物使用,同时确保继续保护人类和动物健康。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Contents Production and Characterization of Human Monoclonal Antibodies from the Cells of A(H1N1)pdm2009 Influenza Virus Infected Indian Donors Editorial: Preventive Vaccination Stabilization of Outer Domain of gp120 from HIV-1 Subtype C for Vaccine Immunogen Design Haloarchaeal Gas Vesicle Nanoparticles Displaying Salmonella Antigens as a Novel Approach to Vaccine Development
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1